Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

High-resolution reconstruction of cell-type-specific transcriptional regulatory processes from bulk sequencing samples.

Nature biotechnology·2026
Same author

Promoter reinforcement supports transcriptional resilience in drug-resistant cancer.

Nature structural & molecular biology·2026
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same author

Optimized Ex Vivo Human Liver Slice Culture Maintains Extended Viability and Function for Hepatotoxicity Testing.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model.

Nature communications·2026
Same author

Phosphatidylserine and RhoB connect PI4P and PA metabolism to maintain plasma membrane identity.

The Journal of cell biology·2026

相关实验视频

Updated: Jan 17, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

一种双阴性前列腺癌亚型易受SWI/SNF向降解分子的伤害.

Phillip Thienger1, Irene Paassen2, Xiaosai Yao3

  • 1University of Bern Bern Switzerland.

Cancer research
|January 14, 2026
PubMed
概括

针对SWI/SNF ATPases的蛋白质溶解向嵌合体 (PROTAC) 疗法在治疗抵抗割的前列腺癌 (CRPC) 中表现有前途. 这些疗法对AR依赖和WNT信号依赖CRPC亚型都有效.

更多相关视频

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

676

相关实验视频

Last Updated: Jan 17, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

676

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 癌症治疗方法 癌症治疗方法

背景情况:

  • 针对SWI/SNF ATPases的蛋白质溶解向嵌合体 (PROTAC) 疗法干扰了依赖AR的割耐性前列腺癌 (CRPC-AR) 中的雄激素受体 (AR) 信号传递.
  • 针对AR阴性CRPC的SWI/SNF向剂的疗效在很大程度上仍未被探索.
  • 具有AR阴性CRPC,特别是WNT信号依赖亚型 (CRPC-WNT),代表着一个重要的未满足的临床需求.

研究的目的:

  • 研究SWI/SNF向剂在AR阴性CRPC中的治疗潜力.
  • 阐明SWI/SNF枯竭影响CRPC-WNT细胞的机制.
  • 为了确定晚期前列腺癌的新疗法策略.

主要方法:

  • 用SWI/SNF向的PROTAC处理CRPC细胞系和有机体模型.
  • 评估细胞活力和信号通路的改变.
  • 耗尽SWI/SNF ATPase SMARCA4并分析其下游目标,包括TCF7L2和MAPK信号.

主要成果:

  • 针对SWI/SNF的PROTAC治疗降低了CRPC-AR和CRPC-WNT细胞的活力.
  • 在CRPC-WNT细胞中的SMARCA4枯竭干扰了转录调节器TCF7L2.2.
  • 发现TCF7L2通过MAPK信号轴维持CRPC-WNT的扩散.

结论:

  • 针对SWI/SNF的疗法对AR依赖CRPC和WNT依赖CRPC都有效.
  • 扰乱TCF7L2的DNA结合或抑制MAPK信号传递是CRPC-WNT的一种可行的治疗策略.
  • 这些发现为晚期前列腺癌的新型治疗方法提供了机制基础.